文献速递肿瘤 PET/CT

18F-FDG PET/CT有助于判断R-ISS II和III期多发性骨髓瘤患者的生存结局

18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-09-05

该回顾性研究分析167例新诊断多发性骨髓瘤患者诱导治疗前18F-FDG PET/CT,发现基线PET/CT阳性(超过3个高代谢局灶性病变或存在髓外病变)是全人群无进展生存和总生存的独立预测因素,且R-ISS II期和III期患者中PET/CT阳性者生存更差。

要点

  • 基线PET/CT阳性定义为超过3个高代谢局灶性病变或存在髓外病变。
  • PET/CT阳性是全人群无进展生存和总生存的独立预测因素。
  • R-ISS II期和III期患者中PET/CT阳性与更差的无进展生存和总生存相关。

核心结论

  • 18F-FDG PET/CT是新诊断多发性骨髓瘤患者生存结局的独立预测因素。
  • 诊断时行18F-FDG PET/CT可能有助于判断R-ISS II期和III期多发性骨髓瘤患者的生存结局。

研究设计与样本

  • 回顾性分析167例新诊断多发性骨髓瘤患者的记录。
  • 所有患者均在诱导治疗前接受18F-FDG PET/CT检查。

主要发现

  • 在全队列中,基线PET/CT显示超过3个高代谢局灶性病变或存在髓外病变的患者,其无进展生存和总生存均显著劣于其他患者。
  • 91%的髓外病变患者同时有超过3个局灶性病变,故PET/CT阳性定义为超过3个局灶性病变或存在髓外病变。
  • 多因素分析显示,PET/CT阳性是全人群无进展生存和总生存的独立预测因素。
  • 55例(46.1%)R-ISS II期患者基线PET/CT阳性,其无进展生存和总生存显著更短。
  • R-ISS III期患者中PET/CT阳性同样与较差的无进展生存和总生存相关。

关键数值与推荐

  • PET/CT阳性定义:超过3个高代谢局灶性病变或存在髓外病变。
  • R-ISS II期患者中46.1%(55例)基线PET/CT阳性。

临床怎么用

  • 原文结论认为诊断时行18F-FDG PET/CT可能有助于判断R-ISS II期和III期多发性骨髓瘤患者的生存结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluated the prognostic role of 18F-FDG PET/CT at baseline in patients with newly diagnosed multiple myeloa (MM) and evaluated the prognostic relevance of 18F-FDG PET/CT for each stage according to the Revised International Staging System (R-ISS). METHOD: We retrospectively analyzed the records of 167 patients with newly diagnosed MM. 18F-FDG PET/CT was performed prior to induction therapy in patients with newly diagnosed MM. RESULTS: In the total cohort, the presence of more than three hypermetabolic focal lesions (FLs) or extramedullary disease (EMD) on baseline PET/CT was associated with significantly inferior progression-free survival (PFS) and overall survival (OS) than other patients. Because most patients (91%) with EMD had more than three FLs, PET/CT positivity was defined as the presence of more than three FLs or the presence of EMD. In multivariate analyses, PET/CT positivity was an independent predictor of PFS and OS in all patients. Fifty-five patients (46.1%) with R-ISS II were PET/CT-positive at baseline and had significantly shorter PFS and OS. PET/CT positivity was also correlated with poor PFS and OS in patients with R-ISS III. CONCLUSION: 18F-FDG PET/CT was an independent predictor of survival outcomes in patients with newly diagnosed MM. In addition, performing 18F- FDG PET/CT at diagnosis may be useful for determining the survival outcomes of MM patients with R-ISS II and III.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jung SH, Kwon SY, Min JJ, et al. 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2018. PMID: 30187105. doi:10.1007/s00259-018-4114-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。